This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spellberg, B.
Right arrow Articles by Ibrahim, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spellberg, B.
Right arrow Articles by Ibrahim, A. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 830-832, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.830-832.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice

Brad Spellberg, Yue Fu, John E. Edwards Jr., and Ashraf S. Ibrahim*

Department of Medicine, Harbor-UCLA Research and Education Institute, Torrance, and David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California

Received 30 July 2004/ Returned for modification 5 August 2004/ Accepted 3 October 2004

We studied the combination of amphotericin B lipid complex (ABLC) and caspofungin in mice with disseminated Rhizopus oryzae. Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone.

* Corresponding author. Mailing address: Division of Infectious Diseases, Harbor-UCLA Research and Education Institute, St. John’s Cardiovascular Research Center, 1124 West Carson St., Torrance, CA 90502. Phone: (310) 222-6424. Fax: (310) 782-2016. E-mail: ibrahim{at}humc.edu.

Antimicrobial Agents and Chemotherapy, February 2005, p. 830-832, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.830-832.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • TONELLI, A. R., OLSON, E. L. (2009). A 19-year-old man with progressive lung infiltrates. Cleveland Clinic Journal of Medicine 76: 635-638 [Full Text]  
  • Dannaoui, E., Schwarz, P., Lortholary, O. (2009). In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrob. Agents Chemother. 53: 3549-3551 [Abstract] [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E. Jr., Spellberg, B. (2009). Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis. Antimicrob. Agents Chemother. 53: 772-775 [Abstract] [Full Text]  
  • Soummer, A., Mathonnet, A., Scatton, O., Massault, P. P., Paugam, A., Lemiale, V., Mira, J. P., Dannaoui, E., Cariou, A., Lortholary, O. (2008). Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis. Antimicrob. Agents Chemother. 52: 1585-1586 [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Fu, Y., Edwards, J. E. Jr., Spellberg, B. (2008). Combination Echinocandin-Polyene Treatment of Murine Mucormycosis. Antimicrob. Agents Chemother. 52: 1556-1558 [Abstract] [Full Text]  
  • Ballester, F., Pastor, F.J., Guarro, J. (2008). In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother 61: 755-757 [Full Text]  
  • Rogers, T. R. (2008). Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61: i35-i40 [Abstract] [Full Text]  
  • Guembe, M., Guinea, J., Pelaez, T., Torres-Narbona, M., Bouza, E. (2007). Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes. Antimicrob. Agents Chemother. 51: 3457-3458 [Full Text]  
  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007). In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrob. Agents Chemother. 51: 2587-2590 [Abstract] [Full Text]  
  • Spellberg, B., Schwartz, J., Fu, Y., Avanesian, V., Adler-Moore, J., Edwards, J. E. Jr, Ibrahim, A. S. (2006). Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 58: 973-979 [Abstract] [Full Text]  
  • Reed, C., Ibrahim, A., Edwards, J. E. Jr., Walot, I., Spellberg, B. (2006). Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis. Antimicrob. Agents Chemother. 50: 3968-3969 [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»